ライフサイエンスコーパス: specific antigen

1 prostate cancer together with KLK3/prostate-specific antigen.

2 ids sequence (HSSKLQL) specific for Prostate Specific Antigen.

3 s both in the absence and in the presence of specific antigen.

4 tion of this population was not dependent on specific antigen.

5 t are associated with pre-operative prostate-specific antigen.

6 t does not depend on identification of tumor-specific antigens.

7 pecific and shows negligible response to non-specific antigens.

8 cognize and eliminate tumor cells expressing specific antigens.

9 lanoma antigen gene (MAGE-I) family of tumor-specific antigens.

10 onse to the WT bacterium, as well as to CO92-specific antigens.

11 hat can specifically bind to prostate cancer-specific antigens.

12 otoxic T cell responses against murine tumor-specific antigens.

13 r T cells become activated against recipient-specific antigens.

14 ic antigen < 10 ng/mL or Gleason 6, prostate-specific antigen, 10 to 20 ng/mL), LDR brachytherapy alo

15 % N0M0; 94% newly diagnosed; median prostate-specific antigen, 66 ng/mL.

16 t host T cells properly primed against tumor-specific antigens after conventional treatment, which ca

17 ) responses against the pancreatic beta-cell-specific antigen (Ag).

18 ove specificity over measurement of prostate-specific antigen alone for detecting cancer with Gleason

19 The focus of tumour-specific antigen analyses has been on single nucleotide

20 reening currently consists of serum prostate-specific antigen and digital rectal examination, followe

21 adjusting for age and longitudinal prostate-specific antigen and digital rectal examination.

22 ydroxyvitamin D) and 2 nonhormones (prostate-specific antigen and ferritin).

23 Prostate-specific antigen and prostate-specific membrane antigen

24 d from them, it is possible to image disease-specific antigens and immune cell subsets.

25 lood was stimulated with the M. tuberculosis-specific antigens and plasma was collected.

26 Identification of specific antigens and T-cell clones that drive the disea

27 is relevant for most MCL cases, although the specific antigens and the precise location of affinity m

28 y processes, which cause expression of tumor-specific antigens and tumor-associated antigens (TAAs) t

29 nalysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examinatio

30 analgesic use, albumin, hemoglobin, prostate-specific antigen, and alkaline phosphatase.

31 cluding human alpha-thrombin, human prostate specific antigen, and human epidermal growth factor rece

32 th progression-free survival (PFS), prostate-specific antigen, and markers of bone turnover.

33 ression-free survival (PFS); tumor, prostate-specific antigen, and pain response; pharmacokinetics; a

34 The adsorbed antigens through specific antigen-antibody binding interactions induced a

35 ity of pCB-(DOPA)4-modified paper sensor for specific antigen-antibody detection was demonstrated via

36 ress, cancer-specific distress, and prostate-specific antigen anxiety.

37 c beads conjugated with antibodies against a specific antigen are used to capture both free molecules

38 CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients but ar

39 ccine consisting of HIV-1-p55gag (gag, group-specific antigen) associated to lysosomal associated pro

40 P = .80), respectively; and 10-year prostate-specific antigen-based recurrence cumulative incidences

41 orted by mapping with a SU C-terminal domain-specific antigen binding fragment.

42 ese two cohorts, independent of the prostate-specific antigen biomarker or Gleason grade, a major exi

43 and explored their relation to the prostate-specific antigen blood value, the bone scan index (BSI),

44 The specific antigens captured by this "TCR trap" method wer

45 th CAR-modified T cells targeting the B-cell-specific antigen CD19.

46 lesion number were correlated with prostate-specific antigen change, clinical impression, and overal

47 Overall, this study both identifies specific antigen combinations for high-priority clinical

48 which cytotoxic T cells (CTLs) target tumor-specific antigens complexed to MHC-I molecules has been

49 vesicle involvement less than 30%, prostate-specific antigen concentration less than 30 ng/mL, and a

50 d radiotherapy using Gleason score, prostate-specific antigen concentration, surgical margin status,

51 t anti-GRP78 AutoAb levels parallel prostate-specific antigen concentrations in patient-derived serum

52 Serum prostate-specific antigen concentrations showed significant corre

53 Men with prostate-specific antigen concentrations up to 15 ng/mL, with no

54 iochemical response as defined by a prostate-specific antigen decline >/= 50% from baseline to at lea

55 Both patients experienced a prostate-specific antigen decline to below the measurable level a

56 At 100 kBq/kg, the duration of prostate-specific antigen decline was less than 4 mo, but if ther

57 tional year; 95% CI, 1.01 to 1.06), prostate-specific antigen density (HR, 1.21 per 0.1 unit increase

58 s associated with intervention were prostate-specific antigen density (HR, 1.38 per 0.1 unit increase

59 ses were categorized by a preceding prostate-specific antigen/digital rectal examination prompt (yes/

60 but have also been suggested to support non-specific antigen diversification of the B-cell repertoir

61 risk for metastatic disease (rapid prostate-specific antigen doubling time or velocity) but otherwis

62 late autoimmune diseases induced with tissue-specific antigens emulsified in adjuvant oils, such as c

63 driven by bystander activation, rather than specific antigen exposure.

64 -functionalized magnetic beads were bound to specific antigens expressed on the target cells.

65 ansmission SPR measurements of free prostate specific antigen (f-PSA), which is similar in size to BS

66 of a cancer protein biomarker, free prostate specific antigen (f-PSA).

67 mous cell carcinoma antigen (SCCA) is a good specific antigen for cancer diagnosis specifically for s

68 formed in 36 subjects with a rising prostate-specific antigen for known (n = 15) or suspected (n = 21

69 ate the clinical potential of CLL1 as an AML-specific antigen for the generation of a novel immunothe

70 The most specific antigen for the serodiagnosis of human C abortu

71 However, specific antigens for many cell types have not been iden

72 nd tested for the detection of free Prostate Specific Antigen (fPSA).

73 cells produced hs2dAb directed against tumor-specific antigens further highlighting the potential use

74 Cleavage of the group-specific antigen (Gag) polyprotein by HIV-1 protease rep

75 e sequential cleavage of the precursor group-specific antigen (Gag) polyprotein by HIV-1 protease.

76 transport is further complicated when group-specific antigen (Gag) protein is expressed, because a s

77 received no previous chemotherapy; prostate-specific antigen greater than 5 ng/mL; and a Karnofsky p

78 , 2007, due to biochemical failure (prostate-specific antigen > 0.2 mg/mL) during androgen-deprivatio

79 .53; 95% CI, 1.41-4.53; P = 0.002), prostate-specific antigen (hazard ratio, 1.03; 95% CI, 1.00-1.05;

80 hological criteria and the analysis of stage-specific antigens (i.e., IGFBP1, PRL).

81 monstrated a sustained reduction in prostate-specific antigen in a patient with CRPC, and another stu

82 trate femtomolar-level detection of prostate-specific antigen in biological fluids, as well as reduce

83 o known as ETAA16, was identified as a tumor-specific antigen in the Ewing family of tumors.

84 stochemically by antibodies that target cell-specific antigens in the cytosol or plasma membrane.

85 proper expression of AIRE-responsive tissue-specific antigens in the thymus.

86 ng loci until a tailored antibody gene for a specific antigen is satisfactorily generated.

87 y ex vivo stimulation of primed T cells with specific antigens is described.

88 ell extracts, and TET2 KD increases prostate-specific antigen (KLK3/PSA) expression.

89 ) and a borderline association with prostate-specific antigen level (P = 0.0458).

90 lobin level (r = -0.521, P < .001), prostate-specific antigen level (r = 0.556, P < .001), lactate de

91 n score (rho, range, 0.03 to 0.20), prostate-specific antigen level (rho, range, -0.07 to 0.10), whil

92 n tDV and best percentage change in prostate-specific antigen level and circulating tumor cell count

93 gistic regression; correlation with prostate-specific antigen level and circulating tumor cell count

94 Prostate-specific antigen level at the time of PET correlated sig

95 s suspected when an increase in the prostate-specific antigen level is detected after radical treatme

96 e [IQR], 61-72) years, median (IQR) prostate-specific antigen level of 43 (18-88) ng/mL.

97 d Gleason scores of 7-10 and a mean prostate-specific antigen level of 7.8 mug/L (range, 5.4-10.6 mug

98 Eleven patients with a prostate-specific antigen level of at least 4 ng/mL (4 mug/L) and

99 The rate of a prostate-specific antigen level of less than 0.2 ng per millilite

100 e cancer, particularly those with a prostate-specific antigen level of less than 10 ng/mL and Gleason

101 a reduction of at least 50% in the prostate-specific antigen level or a confirmed reduction in the c

102 radiotherapy, and the median (IQR) prostate-specific antigen level was 146 (51-354).

103 e T1c/T2a; Gleason score, </=6; and prostate-specific antigen level, <10 ng/mL) or breast cancer (in

104 with biochemical recurrence (median prostate-specific antigen level, 1.31 ng/mL; interquartile range,

105 tate-specific antigen relapse (mean prostate-specific antigen level, 5 ng/mL; range, 0.25-294 ng/mL),

106 patients (n = 134) matched for age, prostate-specific antigen level, and stage were selected from a p

107 Hypofractionation, pretreatment prostate-specific antigen level, Gleason score, and clinical tumo

108 At multivariate analysis, prostate-specific antigen level, primary Gleason grade greater th

109 tal examination results or elevated prostate-specific antigen levels (age groups: 41-50 years, 51-60

110 f circulating MDSCs correlates with prostate-specific antigen levels and metastasis in patients with

111 ineate the relationship between the prostate-specific antigen levels and the diffusion parameters as

112 by applying mathematical models to prostate-specific antigen levels as the representation of tumour

113 Hematocrit and prostate-specific antigen levels increased more in testosterone g

114 -2, localized prostate cancer, with prostate-specific antigen levels less than 50 ng/mL, and enrolled

115 A decrease in prostate-specific antigen levels was noted in 45 of 56 patients (

116 c status, renal function, and serum prostate-specific antigen levels were documented before and after

117 biopsy-naive patients with elevated prostate-specific antigen levels who underwent multiparametric MR

118 n rates even in the presence of low prostate-specific antigen levels.

119 te risk prostate cancer (Gleason 7, prostate-specific antigen < 10 ng/mL or Gleason 6, prostate-speci

120 All patients had a rising level of prostate-specific antigen (mean +/- SD, 13.5 +/- 11.5) and noncon

121 e, biopsy at 12-month intervals and prostate-specific antigen measurement and digital rectal examinat

122 e gut-associated lymphoid tissue (GALT) by a specific antigen migrate to the liver and cause cholangi

123 ure was defined with the use of the prostate-specific antigen nadir + 2-ng/mL definition), freedom fr

124 rides, and a trisaccharide fragment of the O-specific antigen of Vibrio cholerae O139 were synthesize

125 exposure of the memory T cell population to specific antigen or bystander activation, this reservoir

126 7 prostate cancers, independent of prostate-specific antigen or nomogram score.

127 f cells with the same receptor responding to specific antigens, or directly on single cells with no r

128 1gp49) which binds and cleaves B-band LPS (O-specific antigen, OSA) of Pseudomonas aeruginosa PAO1.

129 ne phosphatase (P = 0.0014) but not prostate-specific antigen (P = 0.47).

130 ons included the following: SUV and prostate-specific antigen percentage change at 6 mo (P = 0.014) a

131 vity and the CD44(high)/CD24(low)/epithelial specific antigen-positive fraction.

132 Our data suggest that specific antigen-presenting cell subsets and the inhibit

133 l key secondary end points: time to prostate-specific antigen progression (HR, 0.19; 95% CI, 0.14 to

134 symptomatic, local, or biochemical (prostate-specific antigen) progression.

135 Presence of prostate-specific antigen (proxy for recent sex) and being amenor

136 9 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) >/= 10 ng/mL or Gleason >/= 7, or

137 All patients had a rising level of prostate-specific antigen (PSA) (range, 0.3-119.0 ng/mL; mean, 10

138 ces Task Force (USPSTF) discouraged prostate-specific antigen (PSA) -based prostate cancer screening.

139 he therapeutic response measured by prostate-specific antigen (PSA) 2 mo after RLT.

140 erapy (SRT) for men with detectable prostate-specific antigen (PSA) after radical prostatectomy for p

141 erapeutic response as determined by prostate-specific antigen (PSA) and alkaline phosphatase (ALP), a

142 We determine kon and koff for prostate-specific antigen (PSA) and compare to gold-standard valu

143 Serum prostate-specific antigen (PSA) and Expanded Prostate Index Compo

144 high Gleason score, clinical stage, prostate-specific antigen (PSA) and extent of disease, as well as

145 We determine kon and koff for prostate-specific antigen (PSA) and make a comparison to gold-sta

146 ate MR imaging in men with elevated prostate-specific antigen (PSA) and negative transrectal ultrason

147 evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the conte

148 s decorated with antibodies against prostate specific antigen (PSA) and prostate specific membrane an

149 to diagnose prostate cancer (PCa): prostate-specific antigen (PSA) and spondin-2 (SPON2).

150 icantly repressed the expression of prostate-specific antigen (PSA) and TMPRSS2, two AR-targeted gene

151 The prostate-specific antigen (PSA) assays currently employed for the

152 ith FETs for sensitive detection of prostate specific antigen (PSA) at clinically relevant concentrat

153 e gold content allowed detection of Prostate-Specific Antigen (PSA) at the low attog mL(-1) level.

154 ned to utilize for the detection of prostate specific antigen (PSA) based on three different generati

155 Refractive index-based sensing of prostate specific antigen (PSA) both in buffer and serum was then

156 ratification systems use presenting prostate-specific antigen (PSA) concentration, biopsy Gleason gra

157 ific quality of life, health worry, prostate-specific antigen (PSA) concern, and outlook on life.

158 Men who did not achieve >/= 30% prostate-specific antigen (PSA) decline by cycle 4 (C4) switched

159 sion criterion for this study was a prostate-specific antigen (PSA) doubling time of less than 12 mo

160 Intervention was offered for a prostate-specific antigen (PSA) doubling time of less than 3 year

161 n serum of as low as 25 pg/ml total prostate specific antigen (PSA) during 30-min assay.

162 s have also been found to influence prostate specific antigen (PSA) expression levels and potentially

163 We demonstrate how prostate specific antigen (PSA) expression varies over several or

164 h strong androgen receptor (AR) and prostate-specific antigen (PSA) expression.

165 CT is increasingly used in men with prostate-specific antigen (PSA) failure after radical prostatecto

166 d trials (RCTs) relating to reduced prostate-specific antigen (PSA) failure, yet whether this early e

167 Surveillance was performed with prostate-specific antigen (PSA) follow-up every 3 months, with re

168 d real-time reversible detection of prostate specific antigen (PSA) from 1 to 1,000 nM in 100 mM phos

169 For the measurements of prostate-specific antigen (PSA) in 50% serum using the proposed m

170 S2 biosensor to electrically detect prostate specific antigen (PSA) in a highly sensitive and label-f

171 ndothelial growth factor (VEGF) and prostate-specific antigen (PSA) in human serum for early diagnosi

172 bel-free and real-time detection of prostate specific antigen (PSA) in human serum using silicon nano

173 6-FAM) capable of rapidly capturing prostate specific antigen (PSA) in human serum, cost-effective an

174 of a surrogate peptide (SVILLGR) of prostate specific antigen (PSA) in multiple serum samples.

175 aptasensor to detect the biomarker prostate specific antigen (PSA) in serum.

176 Prostate-specific antigen (PSA) is a biomarker for monitoring tum

177 Prostate specific antigen (PSA) is a widely used serum marker for

178 cintigraphy, clinical data, and the prostate-specific antigen (PSA) level at baseline and 8 wk after

179 Measure prostate-specific antigen (PSA) level every 6 to 12 months for th

180 on therapy (ADT), as reflected by a prostate-specific antigen (PSA) level higher than 4.0 ng/mL after

181 Prostate-specific antigen (PSA) level in midlife predicted future

182 Median prostate-specific antigen (PSA) level was 1.99 ng/mL (range, 0.2-

183 His prostate-specific antigen (PSA) level was 7.1 ng/mL.

184 The 24-hour post-PAE prostate-specific antigen (PSA) level was registered in 133 patie

185 complete datasets for RT, surgery, prostate-specific antigen (PSA) level, Gleason score, and Charlso

186 tive biopsy findings with increased prostate-specific antigen (PSA) level, or (c) had a prior history

187 ent characteristics, including age, prostate-specific antigen (PSA) level, PSA density, race, digital

188 ersistently or recurrently elevated prostate-specific antigen (PSA) level.

189 mination (DRE) results but elevated prostate-specific antigen (PSA) levels (4-20 ng/mL) who were refe

190 scan results (P < 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were associate

191 MA I&T PET/CT because of increasing prostate-specific antigen (PSA) levels after radical prostatectom

192 ated irrespective of Gleason grade, prostate-specific antigen (PSA) levels and pathological tumor-nod

193 t statistical model of longitudinal prostate-specific antigen (PSA) levels and risks for biopsy upgra

194 es have a low detection rate at the prostate-specific antigen (PSA) levels at which targeted salvage

195 Prostate-specific antigen (PSA) levels have been used for detecti

196 iopsy outcomes in 499 patients with prostate-specific antigen (PSA) levels of 2 to 20 ng/mL.

197 nce of metastatic events and higher prostate specific antigen (PSA) levels, with similar trends obser

198 tate cancer patients: both CTCs and prostate-specific antigen (PSA) mRNA sequences were detected in a

199 red eighteen patients with a median prostate-specific antigen (PSA) of 6.4 ng/mL (range, 2.2-158.4 ng

200 cancer or T1-2 disease with either prostate-specific antigen (PSA) of more than 40 mug/L or PSA of 2

201 were referred for elevated level of prostate-specific antigen (PSA) or abnormal digital rectal examin

202 nued until radiologic, clinical, or prostate-specific antigen (PSA) progression; otherwise, treatment

203 grade, advanced pT stage, and early prostate-specific antigen (PSA) recurrence in all cancers (P < 0.

204 13 circulating tumor cell (CTC) and prostate-specific antigen (PSA) response end points in five prosp

205 Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) and whether ET

206 status (positive vs. negative) and prostate-specific antigen (PSA) response rates (the primary end p

207 sociations between AR-V7 status and prostate-specific antigen (PSA) response rates, PSA progression-f

208 Main Outcomes and Measures: Prostate-specific antigen (PSA) response, time receiving therapy,

209 We examined >/= 50% prostate-specific antigen (PSA) responses, PSA progression-free s

210 on on enzalutamide with a continued prostate-specific antigen (PSA) rise after enzalutamide treatment

211 Prostate-specific antigen (PSA) screening for prostate cancer is

212 guidelines have recommended against prostate-specific antigen (PSA) screening for prostate cancer.

213 rly detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but c

214 nsitive and label free detection of prostate specific antigen (PSA) still remains a challenge in pros

215 A serum prostate-specific antigen (PSA) test was 12.4 ng/mL.

216 The development of the prostate specific antigen (PSA) test, and a continuing decrease i

217 alist nurse appointment for a serum prostate-specific antigen (PSA) test.

218 prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain.

219 patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or without

220 for ultrasensitive immunosensing of prostate-specific antigen (PSA) tumor marker.

221 ngle molecules of the cancer marker prostate specific antigen (PSA) using photon-upconversion nanopar

222 The median prostate-specific antigen (PSA) value was 1.0 ng/mL (mean, 4.7 ng

223 Interestingly, on considering prostate-specific antigen (PSA) value, (64)CuCl2 PET/CT had a hig

224 o standard-of-care imaging at serum prostate-specific antigen (PSA) values low enough to affect targe

225 rd, data were compared with current prostate-specific antigen (PSA) values, Gleason score (GS), and d

226 tamer with established affinity for prostate specific antigen (PSA) was complexed with PSA prior to b

227 Prostate-specific antigen (PSA) was determined every 4 wk.

228 trochemical sensor for detection of prostate specific antigen (PSA) was developed using surface impri

229 growth factor receptor 2 (HER2) and prostate specific antigen (PSA), and is also capable of specifica

230 ells (CTCs), bone biomarkers, serum prostate-specific antigen (PSA), and symptomatic skeletal events

231 tients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemi

232 prostate adenocarcinoma (PC), serum prostate-specific antigen (PSA), greatly overestimates PC populat

233 an chorionic gonadotropin (hCG) and prostate specific antigen (PSA), in serum samples.

234 ited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screenin

235 Prostate cancer biomarker proteins, prostate specific antigen (PSA), prostate specific membrane antig

236 The proteins are prostate specific antigen (PSA), prostate specific membrane antig

237 valuated in multiple studies: %free prostate-specific antigen (PSA), PSA velocity, PSA doubling time,

238 rce (USPSTF) recommendation against prostate-specific antigen (PSA)-based screening for this age grou

239 To examine whether the use of prostate-specific antigen (PSA)-based screening in patients with

240 it immunoglobulin G (IgG) and human-prostate-specific antigen (PSA).

241 e sandwich immunoassay detection of prostate specific antigen (PSA).

242 owth factor receptor-2 (HER-2), and prostate specific antigen (PSA).

243 rgins, and detectable postoperative prostate-specific antigen (PSA).

244 asensor to make direct detection of prostate specific antigen (PSA, a biomarker of prostate cancer) u

245 can be estimated by measuring serum prostate-specific antigen (PSA, a PCa biomarker in blood), which

246 lute 20% difference in undetectable prostate-specific antigen (PSA; </= 0.2 ng/mL) rate at 28 weeks (

247 (T1 to 2a, Gleason score </= 6, and prostate-specific antigen [PSA] 10.1 to 20 ng/mL; T2b to 2c, Glea

248 formance of 4 candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir >0.5 ng/mL, PS

249 Efficacy measures (time to prostate-specific antigen [PSA] progression and time to clinical

250 al stage, T1c; Gleason score, </=6; prostate-specific antigen [PSA], <10 ng/mL; PSA density <0.15 ng/

251 urvival [rPFS], >/= 50% decrease of prostate-specific antigen [PSA50], and pain response at 12 weeks)

252 ucing alphabeta T cell clones with psoriasis-specific antigen receptors exist in clinically resolved

253 st time a crucial role of CD4(+) T cells and specific antigen recognition in the progression from com

254 PCa (5 with primary PCa and 5 with prostate-specific antigen recurrence after radical prostatectomy)

255 correlated with Gleason scores and prostate-specific antigen recurrence.

256 e quaternary structure of the secreted tumor-specific antigen reduces its immunogenicity.

257 ean age, 68 y; range, 44-87 y) with prostate-specific antigen relapse (mean prostate-specific antigen

258 eening for prostate cancer based on prostate-specific antigen remains controversial due to the high r

259 oportion of patients with a >/= 50% prostate-specific antigen response (81% v 31%; P < .001); and rad

260 Prostate-specific antigen response and hematologic toxicity were

261 le response, mainly as defined by a prostate-specific antigen response of more than 50%, comparable t

262 Main Outcomes and Measures: Prostate-specific antigen response rate (decline >/=50% from base

263 Prostate-specific antigen response rate to enzalutamide treatment

264 xploratory analyses showed a higher prostate-specific antigen response rate with ipilimumab (23%) tha

265 es in progression-free survival and prostate-specific antigen response rates suggest antitumor activi

266 The initial prostate-specific antigen response showed no correlation with tre

267 every 2 wk by laboratory tests, the prostate-specific antigen response was checked every 4 wk, and ot

268 Prostate-specific antigen responses to ipilimumab were also assoc

269 Prostate-specific antigen responses were achieved in both AR-V7-p

270 4; PSMA expression, rho = 0.47; and prostate-specific antigen, rho = 0.52).

271 BCR was defined as 2 consecutive prostate-specific antigen rises of at least 0.2 ng/mL.

272 Studies demonstrate that use of prostate-specific antigen screening decreased significantly follo

273 rce (USPSTF) recommendation against prostate-specific antigen screening in 2012.

274 ion against routine population-wide prostate-specific antigen screening.

275 presentation of symptoms, including prostate-specific antigen, serum creatinine, urine cytology, imag

276 ssues, and there is a paucity of truly tumor-specific antigens shared across tumor types.

277 o an antibody directed against the ATII cell-specific antigen surfactant protein-C (SP-C) then admini

278 T cells redirected to specific antigen targets with engineered chimeric antige

279 Prostate-specific antigen testing every 4 to 6 months is reasonab

280 rveillance protocols should include prostate-specific antigen testing, digital rectal examinations, a

281 Mammography, prostate-specific antigen testing, or fecal immunochemical testin

282 of circulating anodic antigen, a Schistosoma-specific antigen that is steadily secreted by adult worm

283 ated differences in the expression of tissue-specific antigens that are controlled by the autoimmune

284 cells displayed enhanced expression of stage-specific antigens that extravillous CTBs normally upregu

285 inversely correlated with levels of prostate-specific antigen, the main prognostic factor in prostate

286 of biomaterial scaffolds loaded with disease-specific antigens to identify and study rare, therapeuti

287 al because these cells can be raised against specific antigens to limit autoimmunity.

288 pressing Simian immunodeficiency virus group specific antigen/transactivator of transcription (SIV(ma

289 expression of AR and its effectors prostate-specific antigen, transmembrane protease serine 2, FK506

290 by displaying a diverse repertoire of tissue-specific antigens (TSAs) that are also shared by tumors.

291 ng the expression of a diverse set of tissue-specific antigens (TSAs), which are presented and help t

292 l) and tumor characteristics (serum prostate-specific antigen, tumor grade and clinical stage) and by

293 ns limited by the rarity of targetable tumor-specific antigens, tumor-mediated immune suppression, an

294 Men with high serum prostate specific antigen usually undergo transrectal ultrasound-

295 ts with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-202 ng/mL

296 0.74, respectively, P < 0.001) and prostate-specific antigen values (r = 0.57 and 0.54, respectively

297 nce after primary treatment (median prostate-specific antigen values obtained at the time of PET/CT s

298 ated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23-184).

299 ltivariable analysis, GC and pre-RP prostate-specific antigen were independent predictors of metastas

300 t directs the expression of otherwise tissue-specific antigens, which leads to the elimination of aut